Biograph mct flow 64

For PET/CT acquisition Siemens Biograph was used until January 2014 and since then Biograph mCT Flow 64 (Siemens Medical Solutions AG, Erlangen, Germany) 45 to 90 minutes after the intravenous injection of 52 to 260 MBq of 68 Ga-DOTANOC, -DOTATOC, or DOTATATE PET/CT images were acquired from the skull to the middle part of the thigh. Contrast-enhanced CT (ceCT, spiral CT using Biograph mCT Flow 64) was acquired after intravenous administration of 60 to 100 mL nonionic iodinated contrast. Images were evaluated by 2 experienced nuclear medicine specialists. Any area with intensity greater than background, which could not be explained by physiologic activity, was considered to be indicative of tumor tissue. Maximum standardized uptake values (SUVmax) were obtained by drawing circular regions of interest, which were automatically adapted (40% isocontour) to a 3D volume of interest using commercial software provided by the vendor. Responses were evaluated according to European Organization for Research and Treatment of Cancer criteria, which take into consideration the differences in the maximum standardized uptake values (SUVmax) of the target lesions pre-and post-therapy. 28 The PFS was calculated based on progression, as determined by 68 Ga-SSTR PET/CT.

Two patients with mCRPC were assessed before the 177 Lu-PSMA I&T therapy by 68 Ga-PSMA-HBED-CC PET/CT imaging (Biograph mCT Flow 64; Siemens Medical Solutions AG). Contrast-enhanced PET/CT was performed 1-5 d before endoradiotherapy and for followup at 65 6 4 min after intravenous administration of 170 6 23 MBq of 68 Ga-PSMA-HBED-CC. Both patients with progressive mCRPC underwent therapy with 5.7 and 8.0 GBq of 177 Lu-PSMA I&T, respectively, administered intravenously over 15 min. Complete blood counts, parameters of renal function (serum creatinine, blood urea nitrogen), and liver function (albumin, bilirubin, enzymes), as well as tubular extraction rate measured by 99m Tc-mercaptoacetyltriglycine scintigraphy, were documented before and after therapy. Response to therapy was assessed by 68 Ga-PSMA-HBED-CC PET combined with contrast-enhanced CT 8-10 wk after therapy. In addition, biochemical response was documented by means of PSA monitoring.
Patient 2 was a 68-y-old man with progressive metastatic prostatic adenocarcinoma (Gleason score 7) and multiple mediastinal lymph node metastases. The 54-y-old patient 3, with adenocarcinoma-of-the-prostate (Gleason score 9: 4 1 5) status after hormonal therapy and externalbeam radiation therapy, presented with progressive mediastinal and retroperitoneal lymph node metastases and multifocal osseous lesions.